Roflumilast
33 NDCs across 11 manufacturers|26 Generic,7 Brand
Roflumilast is used to treat chronic obstructive pulmonary disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Feb 28, 2011, and the first generic was approved Jul 13, 2018. FDA's Orange Book lists 19 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $63 million on Roflumilast across 388,000 claims for 89,000 beneficiaries.
Roflumilast is available as 33 NDCs from 11 manufacturers (26 generic, 7 brand), with NADAC prices from $0.31 to $14.98 per EA — the most expensive product costs about 48× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
33
26G / 7B
Manufacturers
11
competing in market
Price Spread
$0.31 – $14.98
per EA, 30 of 33 NDCs
7d Activity
avg -1.0% WoW · of 33 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Major Pharmaceuticals manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Phosphodiesterase 4 Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
11 manufacturers producing ROFLUMILAST(2 pricing outliers)
Frequently Asked Questions
What is Roflumilast used to treat?
Roflumilast is used to treat chronic obstructive pulmonary disease, per the National Library of Medicine's MED-RT classification.
When did Roflumilast become available as a generic?
FDA approved the first generic Roflumilast (ANDA) on Jul 13, 2018. The Orange Book currently lists 19 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Roflumilast?
In 2024, Medicare Part D spent $63 million on Roflumilast across 388,000 claims for 89,000 beneficiaries.
How many Roflumilast products are on the market?
The Roflumilast drug market contains 33 NDCs from 11 manufacturers — 26 generic and 7 brand products.
What is the price range for Roflumilast?
NADAC reference prices for Roflumilast range from $0.3113 to $14.9826 per EA — the most expensive product costs about 48× the cheapest. 3 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Roflumilast cheaper than brand?
The average generic NADAC for Roflumilast is $0.8897 per EA, versus $14.9431 for brand-labeled products — brand versions average about 17× the generic price.
Which manufacturers make Roflumilast?
11 manufacturers list Roflumilast in NADAC. Ranked by number of NDCs, the largest are Major Pharmaceuticals (5), AstraZeneca Pharmaceuticals LP (4), Camber Pharmaceuticals Inc. (4), Novadoz Pharmaceuticals LLC (4), Zydus Pharmaceuticals (USA) Inc. (4).
How has the price of Roflumilast changed recently?
Over the past 7 days, 4 Roflumilast NDCs rose and 25 fell, with a market-wide average change of -1.0%.